Literature DB >> 2564029

HIV-induced immunodeficiency. Relatively preserved phytohemagglutinin as opposed to decreased pokeweed mitogen responses may be due to possibly preserved responses via CD2/phytohemagglutinin pathway.

B Hofmann1, K D Jakobsen, N Odum, E Dickmeiss, P Platz, L P Ryder, C Pedersen, L Mathiesen, I B Bygbjerg, V Faber.   

Abstract

We studied the proliferative response of PBL to the mitogens PHA and PWM and Candida albicans Ag in 301 HIV seropositive homosexual men, of whom 55 had AIDS. The responses to PHA were reduced only in the clinically ill HIV seropositive subjects. In contrast, the responses to PWM were profoundly reduced in most HIV seropositive subjects including the asymptomatic group. Further analysis of 16 HIV seropositive subjects showed that the proliferative responses were reduced in both CD4 and CD8 T cell subsets. A total of 15 HIV seropositive individuals with low responses to PWM, of whom seven had AIDS and eight controls were chosen for the following studies. Expression of T3, Ti, delta receptors, and CD2 was investigated and showed an increased percentage of CD2 receptors positive cells in HIV seropositive subjects without AIDS. The proliferative responses of PBL to stimulation with PHA, PWM, antibodies to CD3, or antibodies to CD2 were investigated and showed significant correlation in controls, whereas in contrast, only the responses to PHA and CD2ab correlated in patients with AIDS. The proliferative responses to CD2ab and CD3ab in controls were larger than the responses to both PHA and PWM. In patients, these responses were less suppressed than the responses to PWM indicating that stimulation with mitogens is more complex than a simple stimulation of Ti/T3 and CD2 receptors. Further investigations were done on resting T cells, i.e., lymphocytes depleted of macrophages and pre-activated cells. Addition of PHA to these cells resulted in preactivation with expression of IL-2R (CD25) but not in proliferation. In contrast, addition of PHA plus SRBC, which bind to the CD2 receptors caused IL-2R expression, IL-2 production, and proliferation. Addition of PWM + SRBC did not result in proliferation. A comparison of the responses to PHA + SRBC of resting T cells from 26 HIV seropositive individuals, of whom seven had AIDS and 12 seronegative controls, showed that these responses were normal or only slightly decreased in the 19 seropositive men without AIDS whereas it was decreased in AIDS patients. Nevertheless, all AIDS patients showed clear-cut responses in this assay. Thus, the discrepancy between responses to PHA and PWM may be explained by an at least partially preserved function of the PHA/CD2-dependent pathway. We suggest that the defect induced by the HIV infection primarily concerns T3/Ti-induced responses.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2564029

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  Microbial immunomodulators: mannoprotein constituents ofCandida albicans with immunomodulatory activity in lymphocyte cultures of normal, glioma-bearing and HIV-infected subjects.

Authors:  A Cassone; I Quinti; C M Ausiello; C Palma; M J Gomez; A Maleci
Journal:  Cytotechnology       Date:  1991-02       Impact factor: 2.058

2.  Do beta-chemokines have clinical relevance in HIV infection?

Authors:  C E Mackewicz; E Barker; G Greco; G Reyes-Teran; J A Levy
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

3.  High susceptibility of U937-derived subclones to human immunodeficiency virus type 1 infection correlates with accumulation of unintegrated circular viral DNA.

Authors:  M Kameoka; T Kimura; Y Okada; K Fujinaga; T Nakaya; H Takahashi; M Kishi; K Ikuta
Journal:  Virus Genes       Date:  1996       Impact factor: 2.332

4.  Polyclonal B-cell activation reveals antibodies against human immunodeficiency virus type 1 (HIV-1) in HIV-1-seronegative individuals.

Authors:  T Jehuda-Cohen; B A Slade; J D Powell; F Villinger; B De; T M Folks; H M McClure; K W Sell; A Ahmed-Ansari
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

5.  Flow cytometric analysis of the stimulatory response of T cell subsets from normal and HIV-1+ individuals to various mitogenic stimuli in vitro.

Authors:  E Medina; N Borthwick; M A Johnson; S Miller; M Bofill
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

6.  Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115.

Authors:  Allan R Tenorio; Hongyu Jiang; Yu Zheng; Barbara Bastow; Daniel R Kuritzkes; John A Bartlett; Steven G Deeks; Alan L Landay; Sharon A Riddler
Journal:  AIDS Res Hum Retroviruses       Date:  2009-02       Impact factor: 2.205

7.  Human immunodeficiency virus proteins induce the inhibitory cAMP/protein kinase A pathway in normal lymphocytes.

Authors:  B Hofmann; P Nishanian; T Nguyen; P Insixiengmay; J L Fahey
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

8.  Impaired proliferative capacity and abnormal cytokine profile of naive and memory CD4 T cells from HIV-seropositive patients.

Authors:  A Cayota; F Vuillier; D Scott-Algara; V Feuillie; G Dighiero
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

9.  CD4+ T cells from CD4C/HIVNef transgenic mice show enhanced activation in vivo with impaired proliferation in vitro but are dispensable for the development of a severe AIDS-like organ disease.

Authors:  Xiaoduan Weng; Elena Priceputu; Pavel Chrobak; Johanne Poudrier; Denis G Kay; Zaher Hanna; Tak W Mak; Paul Jolicoeur
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  Cytokine production by cats infected with feline immunodeficiency virus: a longitudinal study.

Authors:  C E Lawrence; J J Callanan; B J Willett; O Jarrett
Journal:  Immunology       Date:  1995-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.